Posted by Michael Wonder on 12 Jul 2026
Organogenesis announces FDA acceptance of biologics license application for ReNu for the management of symptomatic knee osteoarthritis
6 July 2026 - Organogenesis today announced that the US FDA has completed their filing determination and accepted for review the Company's biologics license application for ReNu, a cryopreserved, amniotic suspension allograft developed for the treatment of pain in symptomatic knee osteoarthritis.
The FDA has set a PDUFA target action date of 24 April 2027.
